Although sitagliptin has been suggested by several studies to reduce PD risk [36, 37], any protective effect of this DPP-4 inhibitor may be negated by the tau phosphorylation associated with its long-term use and use at a high cumulative dosage [20]. This evidence concerns the gene MAPT and Parkinson disease.